 
              Hester Biosciences Limited has reported Consolidated financial results for the period ended June 30, 2023.
Financial Results (Q1 FY2024) - QoQ Comparison 
The company has reported total income of Rs.  88.998 crores during the period ended June 30, 2023 as compared to Rs. 70.487 crores during the period ended March 31, 2023.
The company has posted net profit / (loss) of Rs. 5.869 crores for the period ended June 30, 2023 as against net profit / (loss) of Rs. 4.531 crores for the period ended March 31, 2023.
The company has reported EPS of Rs. 7.89 for the period ended June 30, 2023 as compared to Rs. 6.72 for the period ended March 31, 2023.
                    
       | Total Income | ₹ 88.998 crs | ₹70.487  crs |  26.26% | 
      | Net Profit | ₹5.869 crs | ₹4.531  crs |  29.53% | 
      | EPS | ₹7.89 | ₹6.72 |  17.41% | 
Financial Results  (Q1 FY2024) - YoY Comparison  The company has reported total income of Rs. 88.998 crores during the period ended June 30, 2023 as compared to Rs.53.818 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs.5.869 crores for the period ended June 30, 2023 as against net profit / (loss) of Rs.3.968 crores for the period ended June 30, 2022.
The company has reported EPS of Rs.7.89 for the period ended June 30, 2023 as compared to Rs.4.19 for the period ended June 30, 2022.
                    
      | Total Income | ₹ 88.998 crs | ₹53.818 crs |  65.37% | 
      | Net Profit | ₹5.869  crs | ₹3.968 crs |  47.91% | 
      | EPS | ₹7.89 | ₹4.19 |  88.31% | 
 
Shares of Hester Biosciences Limited was last trading in BSE at Rs. 1773.70 as compared to the previous close of Rs. 1729.00. The total number of shares traded during the day was 2460 in over 661 trades.
The stock hit an intraday high of Rs. 1928.45 and intraday low of 1703.10. The net turnover during the day was Rs. 4479729.00.
              
Source : Equity Bulls
              Keywords
                                       
                                               HesterBiosciences 
                                               Q1FY24 
                                               ResultUpdate